Storti will be responsible for building the teams and culture that drive PathAI’s next phase of growth
BOSTON — June 30, 2022 — PathAI, a global leader in AI-powered pathology, today announced that Elizabeth Storti has been promoted to Chief People Officer. Storti has served in multiple roles since joining PathAI in 2018, including most recently as Vice President of Finance & Operations. Storti led the company’s $240M in financing over multiple fundraises, helmed the acquisition of Poplar Healthcare and the integration of Poplar employees into PathAI, designed and optimized compensation and benefits as the company rapidly scaled, and oversaw the creation of the new headquarters as well as several key initiatives to promote diversity and culture.
“Elizabeth is a proven leader with a deep understanding of PathAI’s complex and interconnected business. Her analytical approach combined with her passion for developing talent and collaboration have played a large part in our growth trajectory,” said Andy Beck, co-founder and CEO of PathAI. “She is a valued member of our executive leadership team and her contributions to PathAI over the last four years have helped us grow to over 700 employees globally. She is the ideal person to help lead the next stage of growth of our team and our culture as Chief People Officer.”
Prior to joining PathAI, Storti held finance and operations roles at Vestmark, Bain Capital, Vitale Caturano, and Deloitte, where she gained extensive experience in creating leading teams, developing talent equity and debt fundraising to scale organizations, M&A, long-term planning and prioritization of investments, and cross-functional operational strategy. Her proven track record as a finance and operations leader and exceptional ability to build and develop cross-functional teams will power PathAI’s growth strategy in the years ahead.
“The great resignation led to more than 40 million Americans voluntarily leaving their jobs in pursuit of more meaningful opportunities, work/life balance and better pay, making clear that employees want more from their employers and that people will be the most strategic investment in our future,” Storti said. “As pathology is in the midst of a revolutionary transformation, PathAI’s ability to attain and retain our teams will give us a competitive edge, positioning us for continued scale and accelerated product development so that we can get our AI-powered pathology innovations to market faster.”
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com.